---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001422"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:36:47.795199+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024

## Summary
- Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.
- Net loss $5.3M vs $6.5M YoY; R&D expense $3.5M (-9% YoY), G&A $2.2M (-31% YoY).
- FDA cleared IND for NPM-119 (six-month GLP-1 implant for type 2 diabetes) in June 2024.
- First-in-human LIBERATE-1 study for NPM-115 (obesity implant) expected to start Q4 2024 in Australia, data in 2025.
- Veterinary GLP-1 implant data published in BMC Veterinary Research; 40% of domestic cats overweight.

## SEC filing metadata
- accession: 0001753926-24-001422
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/0001753926-24-001422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001422/vani-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001422
- JSON: https://secwatch.observer/filing/0001753926-24-001422.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.